Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators
|
|
- Brittney Hill
- 5 years ago
- Views:
Transcription
1 Paris, August 28 th 2011 Is TAVI the definitive treatment in high risk patients? Impact Of Coronary Artery Disease In Elderly Patients Undergoing TAVI: Insight The Italian CoreValve Registry Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators Cardiovascular Department and Division of Cardiology Ferrarotto Hospital - University of Catania Catania, Italy
2 Disclosure Proctor physician for CoreValve Medtronic
3 Background Coronary artery disease in patients with degenerative aortic stenosis is a common condition The presence of CAD increases procedural risk with conventional aortic valve replacement When both conditions are present, a strategy of CABG and AVR in the same session is the current standard of care Impact of ischemic heart disease on outcomes of TAVI has not been well delineated yet
4 171 patients Coexisting coronary artery disease negatively impacts procedural outcomes and long-term survival in patients undergoing TAVI 136 patients Presence of CAD or nonrevascularized myocardium was not associated with an increased risk of adverse events
5 First patient June 2007 Methods The Italian CoreValve Registry Since June 2007 a web-based registry was started 14 participating sites Catania, University Pisa, University Brescia, H. Civile Padova, University Milano, S.Ambrogio 663 patients treated with TAVI 359 patients with CAD 54.5% Milano, Niguarda Firenze, Careggi Milano, S.Raffaele Bologna, University Roma, S. Camillo Legnano Firenze, Careggi Bari, University Mirano
6 Methods Endpoints & Definitions Prior Myocardial Infarction Prior PCI Angiographic finding of coronary stenosis >70% Prior CABG One of these Coronary Artery Disease
7 Results Baseline Clinical Characteristics I Overall population (n = 659) CAD group (n = 356) nocad group (n = 303) p value Age, years±sd 81.2± ± ± Female gender, n (%) 368 (55.8) 159 (44.3) 209 (68.9) <0.001* Diabetes mellitus, n (%) 173 (26.2) 106 (29.5) 67 (22.1) 0.026* Hypertension, n (%) 494 (74.9) 270 (75.2) 224 (73.9) Prior acute pulmonary edema, n (%) 212 (32.2) 120 (33.4) 92 (30.4) Prior balloon valvuloplasty, n (%) 112 (16.9) 62 (17.3) 50 (16.5) Prior stroke, n (%) 48 (7.3) 28 (7.8) 20 (6.6) Peripheral vascular disease, n (%) 126 (19.1) 96 (26.7) 30 (9.9) <0.001* COPD, n (%) 139 (21.1) 72 (20.0) 67 (22.1) Cirrhosis Child class A or B, n (%) 13 (1.9) 5 (1.4) 8 (2.6) Prior neoplasia, n (%) 86 (13.0) 52 (14.5) 34 (11.2) 0.198
8 Results Baseline Clinical Characteristics II Overall population (n = 659) CAD group (n = 356) nocad group (n = 303) p value Renal insufficiency, n (%) 154 (23.3) 102 (28.4) 42 (13.9) 0.001* Atrial fibrillation, n (%) 108 (16.4) 41 (11.4) 67 (22.1) 0.001* Prior pacemaker, n (%) 42 (6.4) 22 (6.1) 20 (6.6) Porcelain aorta, n (%) 72 (10.9) 51 (14.2) 21 (6.9) 0.002* Unstable Angina, n (%) 31 (4.7) 24 (6.7) 7 (2.3) 0.001* Prior CABG, n (%) 104 (15.8) 104 (28.9) - - Prior PCI, n (%) 188 (28.5) 188 (52.4) - - Prior MI, n (%) 143 (21.7) 143 (39.8) - - NYHA class III and IV, n (%) 471 (71.5) 246 (68.5) 225 (74.2) CCS class 2, 3 and (15.5) 73 (20.3) 29 (9.6) <0.001* Logistic Euroscore, %±SD 23.1± ± ±12.1 <0.001*
9 Results Baseline Echo characteristics Overall population CAD group nocad group p value (n = 659) (n = 356) (n = 303) Left ventricular ejection fraction, %±SD 51.2± ± ±12.9 <0.001* Peak pressure gradient, mmhg±sd 83.4± ± ±25.0 <0.001* Mean pressure gradient, mmhg±sd 52.1± ± ± * Mitral regurgitation 3+ or 4+, n (%) 41 (6.2) 23 (6.4) 18 (5.9) 0.783
10 Results Procedural variables Overall population CAD group nocad group p value (n = 659) (n = 356) (n = 303) Procedure time, minutes±sd 79.1± ± ± Approach 0.013* Trans-femoral, n (%) 595 (90.3) 312 (86.9) 283 (93.4) Trans-subclavian, n (%) 64 (9.7) 44 (13.1) 20 (6.6) Anesthesia Local, n (%) 476 (72.2) 248 (69.9) 228 (75.2) General, n (%) 183 (27.8) 108 (30.1) 75 (24.8) Device 0.001* CRS 26-mm 403 (61.1) 188 (52.4) 215 (70.9) CRS 29-mm 256 (38.9) 155 (47.6) 101 (33.3)
11 Results Procedural Outcomes Overall population (n = 659) CAD group (n = 356) nocad group (n = 303) p value Procedural success, n (%) 648 (98.3) 351 (97.8) 297 (98.0) Valve-in-Valve, n (%) 24 (3.6) 14 (3.9) 10 (3.3) Post dilatation, n (%) 67 (10.2) 41 (11.4) 26 (8.6) Death, n (%) 6 (0.9) 3 (0.8) 3 (0.9) Myocardial infarction, n (%) 0 (0) 0 (0) 0 (0.0) Stroke, n (%) 8 (1.2) 3 (0.8) 5 (1.6) Conversion to open heart surgery, n (%) 5 (0.8) 3 (0.8) 2 (0.7) MACCE, n (%) 14 (2.1) 6 (1.7) 8 (2.6) Major access site complications, n (%) 13 (1.9) 6 (1.7) 7 (2.3) Cardiac tamponade, n (%) 8 (1.2) 5 (1.4) 3 (0.9) 0.454
12 Survival, probability (%) Results 1-year survival % 84.0% nocad group CAD group N=659 pts Adjusted HR 1.01 (95% CI 0.55 to 1.88) Log Rank: p= Days (time)
13 Freedom from MI, probability (%) Results 1-year freedom from spontaneous MI % 98.0% nocad group CAD group N=659 pts 0.2 Log Rank: p= Days (time)
14 Freedom from MACCE, probability (%) Results 1-year freedom from MACCE % % nocad group CAD group N=659 pts Adjusted HR 0.84 (95% CI 0.46 to 1.53) Log Rank: p= Days (time)
15 Results Subgroups Analysis 1 year MACCE 1 year All-cause death HR 95% LCL 95% UCL P value P interaction HR 95% LCL 95% UCL P value P interaction Angina Angina Age> Age LV-EF> LV-EF Diabetes mellitus Diabetes mellitus Logistic EuroSCORE> Logistic EuroSCORE
16 Results Type of revascularization pre TAVI 100% 80% N=275 pts* 83% 60% 40% 51% 49% 41% 33% 26% 20% 0% 5% 0% 1-vessel 2-vessels 3-vessels 12% Complete revascularization Incomplete revascularization No-revascularization *patents with significant coronary stenosis (not protected by bypass grafting), found at the time of the angiographic screening for TAVI
17 Survival, probability (%) Results Type of revascularization - Mortality % % Complete revascularization Incomplete revascularization No revascularization 81.9% 0.2 N=275 pts 0.0 Log Rank: p= Days (time)
18 Freedom from MACCE, probability (%) Results Type of revascularization - MACCE % % Complete revascularization Incomplete revascularization No revascularization 79.0% 0.2 N=275 pts 0.0 Log Rank: p= Days (time)
19 86 yo Angina CCs3/Pulmonary Edema Aortic Stenosis LM, LAD, Cx disease BAV PCI LM & LAD Study Limitations
20 PCI LAD Endeavor 2.5/18, 2.5/18, 2.75/241 LM Endeavor 3.5/9 NYHA 2 Successful TAVI with CRS 26 1 month later 3 years follow up NYHA class 2
21 Study Limitations Potential differences in TAVI experience among the participating centers Short Follow-up (The presence and extent of CAD is likely to impact long-term survival in patients treated with TAVI, but the length of follow-up reported in this analysis was not adequate to demonstrate this difference) The lack of specific tools such as fractional flow reserve, intravascular ultrasound, quantitative coronary analysis to assess significance of coronary stenosis
22 Conclusions The association of aortic stenosis and CAD is frequent Acute and mid-term outcomes of patients who underwent TAVI with CRS device were not affected by the presence of concomitant CAD In a TAVI setting for elderly, complete revascularization might not be always necessary Heart Team involvement is mandatory in the decision making
23 Conclusions Heart Team Mission Indications for PCI? Timing of PCI? PCI with or without Balloon Valvuloplasty? Complete or incomplete revascularization? Which stent? Reconsider SAVR + CABG? Optimal Medical Therapy?
24 Thank you on behalf of the CoreValve Italian Registry investigators
Alex versus Xience Registry Preliminary report
Interventional Cardiology Network Alex versus Xience Preliminary report Mariusz Gąsior 1,2, Marek Gierlotka 1, Lech Poloński 1,2 1 3rd Department of Cardiology, Medical University of Silesia Centre tor
More informationIncidence and Management of Early Implant Failure after Transcatheter Aortic Valve Implantation
ESC Congress 2010 28 Aug 2010-01 Sep 2010 Stockholm - Sweden Incidence and Management of Early Implant Failure after Transcatheter Aortic Valve Implantation Gian Paolo Ussia, MD Director of Interventional
More informationAortic valve implantation using the femoral and apical access: a single center experience.
Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationValve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal
Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection
More information1-YEAR OUTCOMES FROM JOHN WEBB, MD
1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following
More informationCoronary interventions
Controversial issues in the management of ischemic heart failure Coronary interventions Maciej Lesiak Department of Cardiology, University Hospital in Poznan none DECLARATION OF CONFLICT OF INTEREST CHF
More information2-Year Results of CoreValve Implantation Through the Subclavian Access
Journal of the American College of Cardiology Vol. 60, No. 6, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.014
More informationPotential conflicts of interest
Potential conflicts of interest Speaker's name: Petros Dardas MEDTRONIC proctor for TAVI Intermediate risk 83 FEMALE COAD SEVERE AS NYHA III Mean gradient 35 mmhg, AVA 0.45cm2, SVI 21ml/m2 Paradoxical
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationIncorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More informationAustralia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes
Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes A/ Professor Darren Walters On behalf of the ANZ Source Investigators Director of Cardiology Brisbane, Australia ANZ
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationJ. Schwitter, MD, FESC Section of Cardiology
J. Schwitter, MD, FESC Section of Cardiology CMR Center of the CHUV University Hospital Lausanne - CHUV Switzerland Centre de RM Cardiaque J. Schwitter, MD, FESC Section of Cardiology CMR Center of the
More informationProsthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III On Behalf of the CoreValve US Clinical Investigators
More informationPercutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000
More informationCorrado Tamburino, MD, PhD
Paravalvular leak: acceptable or not Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate School of Cardiology Chief Cardiovascular Department, Director Cardiology Division,
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationFive-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial
Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
More informatione Corrado Tamburino, MD, PhD
Transcatheter Aortic Valve Implantation Stroke: etiology ogy and prevention e Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate School of Cardiology Chief Cardiovascular
More informationTranscatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationIs TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry
Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry E Van Belle, E Teiger, F Juthier, A Vincentelli, B Iung, H Eltchaninoff, J Fajadet,
More informationHow to Prevent Thromboembolic Complications in TAVI
How to Prevent Thromboembolic Complications in TAVI PETER WENAWESER, MD Swiss Cardiovascular Centre, University Hospital, Bern, Switzerland Potential Conflicts of Interest Proctoring and lecture fees from
More informationTRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH
TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH Available systems: Edwards (TA and TF) and Core valve. INTRODUCTION 3 4% 0f > 65 y. 30 40% of elderly denied surgery,.
More informationAortic Stenosis in the Elderly: Difficulties for the Clinician. Are Symptoms Due to Aortic Stenosis?
Aortic Stenosis in the Elderly: Difficulties for the Clinician Are Symptoms Due to Aortic Stenosis? Raphael Rosenhek Department of Cardiology Medical University of Vienna No disclosure European Society
More informationΔΙΑΔΕΡΜΙΚΗ ΑΝΣΙΚΑΣΑΣΑΗ ΑΟΡΣΙΚΗ ΒΑΛΒΙΔΑ αντιμετώπιση επιπλοκών ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC IICE 2012
ΔΙΑΔΕΡΜΙΚΗ ΑΝΣΙΚΑΣΑΣΑΗ ΑΟΡΣΙΚΗ ΒΑΛΒΙΔΑ αντιμετώπιση επιπλοκών ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC IICE 2012 TAVR Technologies Current Generation Devices ~ 50,000 patients treated thru 2011 in > 500 interventional centers
More informationPeri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY)
Peri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY) Thomas Walther, Christian W. Hamm, Gerhard Schuler, Alexander Berkowitsch,
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationInvestigational Device only in the U.S. Not available for sale in the U.S. ACCESS EU European Society of Cardiology
Early hemodynamic and echocardiographic outcomes after percutaneous MitraClip therapy in patients with mitral regurgitation. Preliminary results of the MitraClip arm of the ACCESS EUROPE registry. Jörg
More informationCan Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationSotirios N. Prapas, M.D., Ph.D, F.E.C.T.S.
CORONARY ARTERY REVASCULARIZATION WITH MILD AORTIC STENOSIS: STRATEGIES OF TREATMENT 9 th ANNUAL MEETING OF THE EAB SOCIETY, Pravets, Bulgaria, 2012 Sotirios N. Prapas, M.D., Ph.D, F.E.C.T.S. Director
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationprocedures for severe Aortic stenosis Treatment
Italian OBservational Study of Effectiveness of AVR TAVI procedures for severe Aortic stenosis Treatment Subgroup Analyses Corrado Tamburino SOCIETA' ITALIANA DI CHIRURGIA CARDIACA onlus ITACTA ITALIAN
More informationCoronary Artery Stenosis. Insight from MAIN-COMPARE Study
PCI for Unprotected Left Main Coronary Artery Stenosis Insight from MAIN-COMPARE Study Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Asan Medical Center Current Practice
More informationRisk Patients Before TAVI or AVR
Balloon Aortic Valvuloplasty for Highest Risk Patients Before TAVI or AVR Dariusz Dudek Chair of the Board of the Institute of Cardiology Jagiellonian University, Kraków, Poland Chair, Education & Training
More informationPrince Sultan Cardiac Center Experience Riyadh, Saudi Arabia
Transcatheter Transapical Aortic Valve Implantation Prince Sultan Cardiac Center Experience Riyadh, Saudi Arabia Ahmed Elwatidy, MD,PhD, FRCS S Kassab, MD,S Ahmari, MD, H Amri, MD, H Ismail, MD, A Calafiori,
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationAortic Valve Practice Guidelines: What Has Changed and What You Need to Know
Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center Disclosure Dr. Burke has no conflicts
More informationTAVR y Enfermedad Coronaria. Mauricio G. Cohen, MD, FACC, FSCAI Director, Cardiac Catheterization Lab Associate Professor of Medicine
TAVR y Enfermedad Coronaria Mauricio G. Cohen, MD, FACC, FSCAI Director, Cardiac Catheterization Lab Associate Professor of Medicine CAD and AS Similar Pathological Processes CAD in TAVR Patients (n=390)
More informationPCI vs. CABG From BARI to Syntax, Is The Game Over?
PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease
More informationTrend and Outcomes of Direct Transcatheter Aortic Valve Replacement from a Single-Center Experience
Cardiol Ther (2018) 7:191 196 https://doi.org/10.1007/s40119-018-0115-0 BRIEF REPORT Trend and Outcomes of Direct Transcatheter Aortic Valve Replacement from a Single-Center Experience Anthony A. Bavry.
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationTranscatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients:
Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 1-Year Results from the SURTAVI Clinical Trial Nicolas M. Van
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationDetailed Order Request Checklists for Cardiology
Next Generation Solutions Detailed Order Request Checklists for Cardiology 8600 West Bryn Mawr Avenue South Tower Suite 800 Chicago, IL 60631 www.aimspecialtyhealth.com Appropriate.Safe.Affordable 2018
More informationStable Angina: Indication for revascularization and best medical therapy
Stable Angina: Indication for revascularization and best medical therapy Cardiology Basics and Updated Guideline 2018 Chang-Hwan Yoon, MD/PhD Cardiovascular Center, Department of Internal Medicine Bundang
More informationValvular Intervention
Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationCardiac Care Network of Ontario
Cardiac Care Network of Ontario Cardiac Wait Times Patient Triage Business Rules December 2016 TABLE OF CONTENTS 1. Introduction... 3 1.1. Document Purpose... 3 1.2. Document Structure... 3 2. Algorithms...
More informationTAVI in Korea, How to Avoid Conduction
TAVI in Korea, How to Avoid Conduction Disturbance after CoreValve Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul,
More informationCase Presentations TAVR: The Good Bad and The Ugly
Case Presentations TAVR: The Good Bad and The Ugly Vincent J. Pompili, MD, FACC, FSCAI Professor of Internal Medicine Director of Interventional Cardiovascular Medicine and Cardiac Catheterization Laboratories
More information> 1200 Patients
> 1200 Patients 2002-2008 2008 Transfemoral (n=628) Transapical (n=457) Antegrade N=59 Retrograde N=569 TRAVERCE n=172 RECAST n = 24 REVIVE II n = 106 REVIVAL II n =40 Early First in Man irevive n = 22
More informationAortic Stenosis: Background
Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients Barry George, MD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Aortic Stenosis: Background Severe Symptomatic
More information2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR
TRANSCATHETER AORTIC VALVE REPLACEMENT IN 2018: IS IT NOW THE STANDARD OF CARE? 22 ND ANNUAL COASTAL CARDIAC & VASCULAR CONFERENCE FEBRUARY 17, 2018 R. David Anderson, MD, MS, FACC, FSCAI Professor of
More informationRapid deployment aortic valve replacement for the treatment of severe aortic stenosis in high risk patients. Β. Κόλλιας, Σ. Ματιάτου, Δ. Αγγουράς.
Rapid deployment aortic valve replacement for the treatment of severe aortic stenosis in high risk patients. Οι βιοπροσθετικές αορτικές βαλβίδες ταχείας έκπτυξης στην αντιµετώπιση της σοβαρής αορτικής
More informationWhen should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER
When should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER ICPS, Massy ICV-GVM La Roseraie, Aubervilliers Hôpital FOCH, Suresnes Disclosure Statement of Financial
More informationClinical Outcome in Patients with Aortic Stenosis
Clinical Outcome in Patients with Aortic Stenosis Is the Prognosis Worse in Patients with Low-Gradient Severe Aortic Stenosis? Yoel Angel BSc, Shemy Carasso MD, Diab Mutlak MD, Jonathan Lessick MD Dsc,
More informationWelcome 17 Michigan TAVR Participating Hospitals!
Welcome 17 Michigan TAVR Participating Hospitals! 1 MICHIGAN TAVR BRIEF OVERVIEW HOW AND WHY PRE-TAVR IMAGING EVALUATION AND THE TVT Michael Grossman, MD Co-Director, BMC2 Coordinating Center Why Michigan
More informationTAVI in Rabin Medical Center -
Long-Term Outcomes of 560 Consecutive Patients treated with TAVI and Propensity Score Matched- Analysis of Early Versus New Generation Valves Amos Levi, MD, Uri Landes, MD, Abid R Assali, MD, Katia Orvin,
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationTAVI After PARTNER-2 : The Hamilton Approach
TAVI After PARTNER-2 : The Hamilton Approach James L. Velianou MD FRCPC Interventional Cardiology Hamilton General Hospital St Catharines General Hospital Associate Professor of Medicine McMaster University
More informationAortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC
Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC No Financial Disclosures Aortic Stenosis AS is an insidious disease with a long latency period followed by
More informationΑγγειοπλαστική σε Nόσο Στελέχους: Που βρισκόμαστε. Βάιος Τζίφος Δ/ντής Τμήματος Επεμβατικής Καρδιολογίας Τομέας Καρδιάς Ερρίκος Ντυνάν Hospital Center
Αγγειοπλαστική σε Nόσο Στελέχους: Που βρισκόμαστε. Βάιος Τζίφος Δ/ντής Τμήματος Επεμβατικής Καρδιολογίας Τομέας Καρδιάς Ερρίκος Ντυνάν Hospital Center Δεν έχω οικονομική σχέση με φαρμακευτική εταιρία.
More informationEstablishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS
Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T H E P A R T N E R T R
More informationFor the SURTAVI Investigators
Neurological complications after transcatheter aortic valve implantation with a self-expanding bioprosthesis or surgical aortic valve replacement in patients at intermediate-risk for surgery A. Pieter
More informationSurgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea
Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea Contents Decision making in surgical AVR in old age Clinical results of AVR with tissue valve Impact of 19mm
More informationTAVR: Intermediate Risk Patients
TAVR: Intermediate Risk Patients Oscar A. Mendiz.MD.FACC.FSCAI Director Cardiology & Cardiovascular Institute (ICyCC) Chief Interventional Cardiology Department Board of Directors Hospital & Favaloro University
More informationPatient with low-flow low-gradient aortic stenosis and ischemic cardiomyopathy TAVR and possibly percutaneous revascularization
Patient with low-flow low-gradient aortic stenosis and ischemic cardiomyopathy TAVR and possibly percutaneous revascularization + K Spargias, MD, PhD THV Director Hygeia Hospital Disclosures - Proctor
More informationSeverity of AS Degree of AV calcification (? Bicuspid AV), annulus size, & aortic root
The role of Cardiac Imaging modalities in evaluation & selection of patients for Trans-catheter Aortic Valve Implantation Dr.Saeed AL Ahmari Consultant Cardiologist Prince Sultan Cardaic Center, Riyadh
More information22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2.
Oxford City Transcatheter aortic valve replacement 2017 guidelines Monday 19 th June Jim Newton Oxford Oxford University Hospitals NHS FT How familiar are you with TAVR? 1. First time I have heard about
More informationEdwards Transcatheter AVR: Have the Outcomes Changed after CE Approval?
Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval? Update from PARTNER EU and SOURCE Registries T. Lefèvre Disclosure Statement Cardiologist Interventional cardiologist 1 st PABV in
More informationDr. Jean-Claude Laborde
Medtronic CoreValve Experience Alternative Access (Subclavian) and Technology Evolution of the Medtronic CoreValve TAVI System Dr. Jean-Claude Laborde Glenfield Hospital, Leicester, U.K. St George Hospital,
More informationThe Ross Procedure: Outcomes at 20 Years
The Ross Procedure: Outcomes at 20 Years Tirone David Carolyn David Anna Woo Cedric Manlhiot University of Toronto Conflict of Interest None The Ross Procedure 1990 to 2004 212 patients: 66% 34% Mean age:
More informationVALVULOPATIE: NUOVE SOLUZIONI.
VALVULOPATIE: NUOVE SOLUZIONI www.fisiokinesiterapia.biz Nkomo, Lancet 2006 ELDERLY POPULATION PROJECTION IN USA 65-84 Years Old 85 and Older 77,2 Millions of people 34,8 4,3 30,5 53,8 6,8 47 14,3 62,9
More informationLong-term results (22 years) of the Ross Operation a single institutional experience
Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department
More informationQuality Outcomes Mitral Valve Repair
Quality Outcomes Mitral Valve Repair Moving Beyond Reoperation Rakesh M. Suri, D.Phil. Professor of Surgery 2015 MFMER 3431548-1 Disclosure Mayo Clinic Division of Cardiovascular Surgery Research funding
More informationTranscatheter aortic valve implantation and pre-procedural risk assesment
Transcatheter aortic valve implantation and pre-procedural risk assesment Alec Vahanian,FESC, FRCP(Edin.) Bichat Hospital University Paris VII, Paris, France Disclosures Relationship with companies who
More informationThe FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation
The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation Susheel Kodali, MD Director, Structural Heart & Valve
More informationPrevention and Management of Cardiac Adverse Event
Prevention and Management of Cardiac Adverse Event Carlo Cernetti Department of Interventional Cardiology Mirano (Italy) Cannes MEEC 14 June 2007 Are these risks factors of Haemodynamic Instability
More informationRANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING
AORTIC VALVE DISEASE RANDOMISED TRIALS COMPARING TAVI WITH SAVR STEPHAN WINDECKER DEPARTMENT OF CARDIOLOGY SWISS CARDIOVASCULAR CENTER AND CLINICAL TRIALS UNIT BERN BERN UNIVERSITY HOSPITAL, SWITZERLAND
More informationTAVR IN INTERMEDIATE-RISK PATIENTS
TAVR IN INTERMEDIATE-RISK PATIENTS K. Lampropoulos MD, PhD, FESC, MEAPCI Interventional Cardiologist Evangelismos General Hospital The Burden of Valve Disease Prevalence Survival NATURAL HISTORY OF AS
More informationFRANCE 2 : FRench Aor$c Na$onal Corevalve
: FRench Aor$c Na$onal Corevalve and Edwards Registry Mar$ne Gilard, MD University of Brest, France On behalf of the scien/fic commi2ee and the inves/gators M Laskar, P Donzeau- Gouge, K Chevreul, H Eltchaninoff,
More informationMasterclass III Advances in cardiac intervention. Percutaneous valvular intervention a novel approach
Masterclass III Advances in cardiac intervention Percutaneous valvular intervention a novel approach Professor Roger Boyle CBE National Director for Heart Disease and Stroke London Medical therapy Medical
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Transcatheter Aortic Valve Implantation for Aortic Stenosis Page 1 of 37 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Transcatheter Aortic Valve Implantation
More informationTranscatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
More informationDr.ssa Loredana Iannetta. Centro Cardiologico Monzino
Dr.ssa Loredana Iannetta Centro Cardiologico Monzino Bicuspid aortic valve BAV is the most common congenital cardiac anomaly. Estimated incidence is 2% in general population. 4:1 male predominance. Frequency
More informationAortic Stenosis: UPDATE Anjan Sinha, MD Krannert Institute of Cardiology
Aortic Stenosis: UPDATE 2010 Anjan Sinha, MD Krannert Institute of Cardiology None Disclosures 67-Year-Old Male Dyspnea and angina Class III heart failure No PND or orthopnea 3/6 late peak SEM Diminished
More informationA.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany
Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,
More informationOutcome of elderly patients with severe but asymptomatic aortic stenosis
Outcome of elderly patients with severe but asymptomatic aortic stenosis Robert Zilberszac, Harald Gabriel, Gerald Maurer, Raphael Rosenhek Department of Cardiology Medical University of Vienna ESC Congress
More information30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve. Didier Tchétché, MD On Behalf of the CENTERA Investigators
30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve Didier Tchétché, MD On Behalf of the CENTERA Investigators Speaker's name: Didier Tchétché, MD I have the following potential
More informationSYNTAX score before decision making! Corrado Tamburino, MD, PhD
SYNTAX score in left main - Tamburino TCT Asia Pacific Seoul, 27 April 2011 Slide 1 SYNTAX score before decision making! Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate
More informationAortic Stenosis Background and Breakthroughs in Treatment: TAVR Update
Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update Howard J Broder MD Interventional Cardiology DaVita Medical Group/ Healthcare Partners Cardiology Disclosures for Howard J Broder
More informationPercutaneous Coronary Interventions Without On-site Cardiac Surgery
Percutaneous Coronary Interventions Without On-site Cardiac Surgery Hassan Al Zammar, MD,FESC Consultant & Interventional Cardiologist Head of Cardiology Department European Gaza Hospital Palestine European
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationOptions for my no option Patients Treating Heart Conditions Via a Tiny Catheter
Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter Nirat Beohar, MD Associate Professor of Medicine Director Cardiac Catheterization Laboratory, Medical Director Structural
More information